Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TB006 in Adults With Autism Spectrum Disorder
NCT06500637Phase 2Recruiting
- Sponsor
- Rossignol Medical Center
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing TB006 with Placebo (2 arms). Primary endpoint: Childhood Autism Rating Scale at Week 14. Started Aug 2024; status: recruiting.
02
Drugs
TB006
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06500637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500637.